This combination of Amlodipine and Atorvastatin is indicated in patients where treatment with both agents at the specified doses is appropriate. It is used in conditions such as hypertension, chronic stable angina, and as an adjunct to diet in hypercholesterolemia. It is also beneficial in hypertensive patients with multiple cardiovascular risk factors to reduce the risk of nonfatal myocardial infarction and stroke.

Amlodipine:

• Hypertension: Amlodipine is used for the management of high blood pressure, either alone or in combination with other antihypertensive medications.
• Coronary Artery Disease (CAD): Chronic Stable Angina: Indicated for the treatment of chronic stable angina; it may be used alone or alongside other antianginal or antihypertensive agents.
• Variant (Prinzmetal’s) Angina: Used in confirmed or suspected vasospastic angina, either as monotherapy or in combination with other treatments.
• Angiographically Documented CAD: In patients with recently confirmed CAD (without heart failure or with ejection fraction <40%), amlodipine reduces the risk of hospitalization for angina and lowers the need for coronary revascularization.

Atorvastatin: Atorvastatin is indicated as an adjunct to diet for reducing elevated levels of total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson Types IIa and IIb). It is also used for:

• Treatment of elevated triglycerides (Type IV).
• Management of primary dysbetalipoproteinemia (Type III) in patients who do not respond adequately to diet.
• Reduction of total cholesterol and LDL cholesterol in homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering therapies.
• In acute coronary syndrome, it may be initiated during hospitalization or at discharge if LDL-C levels exceed 100 mg/dL.

Before starting therapy, secondary causes of hyperlipidemia (e.g., uncontrolled diabetes, hypothyroidism, nephrotic syndrome, obstructive liver disease, drug therapy, alcoholism) should be ruled out, and a lipid profile should be assessed.

This combination contains Amlodipine (as amlodipine besilate) and Atorvastatin (as atorvastatin calcium). Amlodipine is a calcium channel blocker that relaxes vascular smooth muscle, leading to reduced peripheral resistance and lower blood pressure. Atorvastatin is a lipid-lowering agent that inhibits HMG-CoA reductase, an enzyme responsible for cholesterol synthesis, thereby reducing cholesterol levels in the blood.

Amlodipine: The usual initial antihypertensive oral dose is 5 mg once daily with a maximum dose of 10 mg once daily. Elderly individuals or patients with hepatic insufficiency may be started on 2.5 mg once daily dose and this dose may be used when adding Amlodipine to other antihypertensive therapy. Dosage should be adjusted according to each patient's need. The recommended dose for chronic stable or vasospastic angina is 5-10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency.

Atorvastatin:

• The patient should be placed on a standard cholesterol-lowering diet before receiving Atorvastatin and should continue on this diet during treatment with Atorvastatin Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb): The recommended starting dose of Atorvastatin is 10 mg daily. The dosage range is 10 to 80 mg once daily. Atorvastatin can be administered as a single dose at any time of the day with or without food.
• Homozygous Familial Hypercholesterolemia: The dosage of Atorvastatin in patients with homozygous FH is 10 to 80 mg daily.
• Patients with renal insufficiency: Renal disease has no influence on the plasma concentrations or lipid effects of Atorvastatin; thus no adjustment of dose is required. Hemodialysis is not expected to significantly enhance the clearance of Atorvastatin since the drug is extensively bound to plasma proteins.
• Patients with hepatic dysfunction: In patients with moderate to severe hepatic dysfunction, the therapeutic response to Atorvastatin is unaffected but exposure to the drug is greatly increased.

Drug interaction with atorvastatin: The risk of myopathy may increase when atorvastatin is used with drugs such as cyclosporine, fibrates, niacin, erythromycin, azole antifungals, and magnesium/aluminum-containing antacids. Antacids may reduce atorvastatin levels but generally do not significantly affect LDL-C reduction. Co-administration with colestipol may lower atorvastatin plasma levels, though lipid-lowering effects remain additive. Concurrent use with digoxin may increase digoxin levels, requiring monitoring. Erythromycin may increase atorvastatin exposure. Use with oral contraceptives may increase hormone levels (norethindrone and ethinyl estradiol), which should be considered during selection.

Drug interaction with amlodipine: Amlodipine may enhance the effects of other antihypertensive agents (e.g., beta-blockers, ACE inhibitors, alpha-blockers, diuretics). However, it does not significantly alter the pharmacokinetics of atorvastatin, digoxin, warfarin, or cyclosporine.

Amlodipine: Contraindicated in patients with known hypersensitivity to amlodipine.
Atorvastatin: Contraindicated in patients with hypersensitivity to any component of the drug, active liver disease, or persistent unexplained elevation of serum transaminases exceeding three times the upper limit of normal.

Amlodipine: Due to gradual vasodilation, acute hypotension is uncommon. However, caution is needed when used with other vasodilators, especially in patients with severe aortic stenosis. In heart failure patients, no significant worsening has been observed in controlled studies, though caution is advised.

Atorvastatin: May increase creatine phosphokinase (CPK) levels and can be associated with myalgia or myopathy. Therapy should be discontinued if significant CPK elevation occurs. Common side effects include constipation, flatulence, dyspepsia, abdominal pain, headache, nausea, myalgia, diarrhea, fatigue, and insomnia.

Safety during pregnancy has not been established. Use of HMG-CoA reductase inhibitors during breastfeeding is not recommended.

Cardiovascular risk: Rarely, patients—especially those with severe coronary artery disease—may experience worsening angina or myocardial infarction after starting calcium channel blockers.

Liver function: Statins may cause abnormalities in liver function tests; monitoring is recommended.

Amlodipine: Use cautiously in patients with severe aortic stenosis or heart failure.

Atorvastatin: Risk of rhabdomyolysis exists, particularly with elevated CPK levels or muscle symptoms; discontinue if necessary.

Pediatrics: Safety and effectiveness of atorvastatin in children have not been established.

Geriatrics: Efficacy and safety in elderly patients are similar to those observed in the general population.

Anti-anginal and lipid-lowering agent.

Store in a cool, dry place away from light and moisture. Keep out of reach of children.